Patrik Eriksson

CEO since January 2024

Born 1967

Education

MSc in Economics and Business Administration from the Stockholm School of Economics.

Other current assignments

Boston University, School of Dental Medicine, Dean’s advisory board.
Harvard University, Harvard School of Dental Medicine, Dean’s advisory board.
University of Pennsylvania, Penn School of Dental Medicine, Board of Overseers.


Principal work experience

President, Nobel Biocare
President, KaVoKerr
President, Ormco Corporation
President and CEO, Carestream Dental LLC

Shareholding in the company

30,000 ordinary shares.
Subscribed for a total of 81,905 warrants and 4,095 employee stock options under LTI 2023.
Subscribed for 550,000 call options in Vimian at market price from Fidelio Vet Holding AB in December 2023.
Allotted 341,000 employee stock options under LTI 2024.

Carl-Johan Zetterberg Boudrie

CFO since 2022

Born 1978

Education

MSc in electrical engineering from the Royal Institute of Technology and MSc in economics from Stockholm University.

Other current assignments

Owner of Calan Consulting AB.


Principal work experience

CEO at Careium AB, CEO and CFO at DORO AB, CFO at Lekolar, Vice President Business Development at Beijer Electronics, and consultant at Capgemini Invent.

Shareholding in the company

5,142 ordinary shares, 0 C shares.
Subscribed for a total of 41,071 warrants in the Company under LTI 2022.
Allotted 150,000 employee stock options under LTI 2024.

Magnus Kjellberg

CEO of Nextmune since 2017

Born 1973

Education

MSc in Business and Economics from the Stockholm School of Economics.

Other current assignments

Chairman and member of the board in a number of subsidiaries within the Group including Nextmune Holding BV, Nextmune BV, Nextmune US LLC, Nextmune AS, Nextmune Scandinavia AB, Nextmune Spain S.L., Nextmune Italy S.r.l., Vetruus Limited and Bova UK Limited.


Principal work experience

VP Corporate Strategy and M&A at Meda.

Shareholding in the company

3,581,047 ordinary shares.
Allotted 150,000 employee stock options under LTI 2024.

Guy C. Spörri

CEO of Movora since 2020

Born 1980

Education

MSc in Management, Technology and Economics from ETH Zürich.

Other current assignments

Chairman of the board of KYON AG and Ossium AG. Board member of KYON Pharma (US).


Principal work experience

CEO of Kyon, General Manager of Joint Replacement Division at Stryker and Sales Manager at Johnson & Johnson.

Shareholding in the company

979,804 ordinary shares.
Subscribed for a total of 8,214 warrants under LTI 2022.
Allotted 140,000 employee stock options under LTI 2024.

Alireza Tajbakhsh

CEO of VetFamily since 2022

Born 1983

Education

MSc in Economics and Business Administration from the Stockholm School of Economics.

Other current assignments

Chairman of the board and board member of a number of subsidiaries within the Group. Board member of Famano AB, Precis Holding AB (Precis Digital), Seenthis AB, Proxer Midco AB and Stiftelsen Vin & Sprithistoriska museet.


Principal work experience

Group CEO of Omnicom Media Group Sweden, COO MTGx and Head of Digital MTG

Chairman of the Board OMD Sweden, Chairman of the Board PHD Sweden, Chairman of the Board Hearts & Science Sweden, Chairman of the Board Drum Sweden. Member of Board Splay Networks & Member of Board Godsmak.se.

Shareholding in the company

299,638 ordinary shares and 125,170 C shares.
Subscribed for a total of 275,000 warrants in the Company under LTI 2022.
Subscribed for a total of 10,000 warrants in the Company under LTI 2023.
Allotted 120,000 employee stock options under LTI 2024.

Stefano Santarelli

CEO of Indical Bioscience since 2021

Born 1981

Education

Bachelor of Economics (Honours) at LUISS Guido Carli University in Rome.

Principal work experience

Ontario Teachers’ Pension Plan (OTPP), Bain & Company, Ernst & Young, TIM Telecom Italia, P&G.


Shareholding in the company

4,500 ordinary shares, 0 C shares.
Subscribed for a total of 82,142 warrants in the Company under LTI 2022.
Subscribed for a total of 81,905 warrants and 4,095 employee stock options under LTI 2023. 
Allotted 100,000 employee stock options under LTI 2024.

Martin Bengtson

Head of M&A since 2021

Born 1981

Education

MSc in Finance from the Stockholm School of Economics.

Other current assignments

Board member of HRR Holding AB and Danzinger Gatt Invest AB.


Principal work experience

Head of M&A at Doktor.se, Group M&A Manager at AniCura and Investment Manager at Nordic Capital.

Shareholding in the company

282,802 ordinary shares.
0 warrants.
Allotted 60,000 employee stock options under LTI 2024.

Maria Dahllöf Tullberg

Head of IR, Communications & Sustainability since 2021

Born 1981

Education

MSc in Accounting and Financial Management from the Stockholm School of Economics.

Principal work experience

Group Communications Director at AniCura, Head of Marketing & Communications at Moderna Försäkringar and Consultant at JKL Group.


Independent of

8,342 ordinary shares, 0 C shares.
Subscribed for a total of 112,689 warrants under LTI 2022. 
Subscribed for a total of 80,000 warrants under LTI 2023.
Allotted 143,612 employee stock options under LTI 2024.

Carl-Johan Ehn

General Counsel since 2022

Born 1974

Education

Master of laws - LLM from Lund University
Bachelor of Business Administration – Finance from Lund University

Other current assignments

Board member of Elding Oscarson Arkitekter AB
Board member of Tapster AB


Principal work experience

Vice President and Chief Counsel International Operations at Zoetis
Assistant General Counsel at Pfizer
Attorney (Advokat) at Mannheimer Swartling Law Firm

Shareholding in the company

19,660 ordinary shares.
Subscribed for a total of 112,689 warrants in the Company under LTI 2022.
Subscribed for a total of 50,000 warrants in the Company under LTI 2023.
Allotted 60,000 employee stock options under LTI 2024.